{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024476","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.534225+00:00","generated_at":"2026-06-21T23:05:03.883742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025","bullets":["Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.","BDC-1001 dose-escalation trial on track to complete enrollment by year-end; topline data and RP2D expected Q1 2023.","BDC-3042 IND-enabling progressing; on track for clinical entry in 2023.","Collaboration revenue $2.1M (up from $0.8M YoY); R&D expense $19.0M, G&A $5.5M.","Loss from operations $22.3M vs $23.5M in Q3 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024476","json":"https://secwatch.observer/filing/0000950170-22-024476.json","markdown":"https://secwatch.observer/filing/0000950170-22-024476.md","text":"https://secwatch.observer/filing/0000950170-22-024476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/0000950170-22-024476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/bolt-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:05:03.883742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8256d046404e7e353565e6cfbb4ec7b4b8e92ef","claim":"Bolt Biotherapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $2.1 million.","evidence_excerpt":"16th, 2022, with a corporate presentation at 1:15 p.m. ET in New York, New York. Third Quarter 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $2.1 million for the third quarter ended September 30, 2022, compared to $0.8 million for the same quarter in 2021. This represents 50% growth over the second quarter of 2022 as Bolt","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/0000950170-22-024476-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}